117 related articles for article (PubMed ID: 1874602)
1. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.
Green JB; Green S; O'Toole RV; Alberts DS; Nahhas WA; Wallace DL
Invest New Drugs; 1991 May; 9(2):191-3. PubMed ID: 1874602
[TBL] [Abstract][Full Text] [Related]
2. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.
Alberts DS; Mason-Liddil N; Stock-Novack D; O'Toole RV; Abbott TM; Salmon SE
Am J Clin Oncol; 1992 Apr; 15(2):146-9. PubMed ID: 1553903
[TBL] [Abstract][Full Text] [Related]
3. Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.
Miller TP; Dahlberg S; Salmon SE; Williamson SK; Belt RJ; Dana BW; Fisher RI
J Clin Oncol; 1991 Jul; 9(7):1204-9. PubMed ID: 2045860
[TBL] [Abstract][Full Text] [Related]
4. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
Vaughn CB; Salmon SE; Fleming TR
Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
McGuire WP; Blessing JA; Berman ML
Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
McGuire WP; Blessing JA; Yordan E; Beecham J
Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
[TBL] [Abstract][Full Text] [Related]
8. Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
Muss HB; Van Echo D; Korzun AH; Henderson IC; Campbell T; Vogelzang NJ; Rice MA; Wood W
Am J Clin Oncol; 1990 Jun; 13(3):233-7. PubMed ID: 2346128
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
Frustaci S; Gasparini G; Veronesi A; Tirelli U; Pacciarini MA; Crivellari D; Zagonel V; Monfardini S
Invest New Drugs; 1987; 5(3):307-9. PubMed ID: 3667167
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing J; Hanjani P; Kramer P;
Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
Fiore J; Kemeny N; Raymond V; Young C
Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
[No Abstract] [Full Text] [Related]
12. New anthracycline analogs in advanced breast cancer.
Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley H; Creasman WT; Sutton G
Gynecol Oncol; 1989 Apr; 33(1):68-70. PubMed ID: 2703169
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
Rigas JR; Kris MG; Gralla RJ; Heelan RT; Marks LD
Invest New Drugs; 1991 May; 9(2):187-90. PubMed ID: 1651908
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.
Locker GY; Hoeltgen T; Kilton L; Krauss S; McNamara M; Blough R; Johnson C
Cancer Treat Rep; 1987; 71(7-8):765-6. PubMed ID: 3300969
[No Abstract] [Full Text] [Related]
18. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
Sridhar KS; Hussein AM; Benedetto P; Ardalan B; Savaraj N; Richman SP
Cancer; 1992 Sep; 70(6):1591-7. PubMed ID: 1516010
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.
Braich TA; Salmon SE; Robertone A; Alberts DS; Jones SE; Miller TP; Garewal HS
Invest New Drugs; 1986; 4(3):269-74. PubMed ID: 3818231
[TBL] [Abstract][Full Text] [Related]
20. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).
Hochster H; Hunt M; Green M; Parkinson D; Smith T
Invest New Drugs; 1990 Aug; 8(3):329-32. PubMed ID: 2272773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
